Form 4: Pfizer Director Narayen Acquires Phantom Stock Units

Pfizer Inc. director Shantanu Narayen acquired 2,058.46 phantom stock units, representing deferred compensation.

Summary

• Shantanu Narayen, a Director at Pfizer Inc., acquired 2,058.46 phantom stock units on June 26, 2026.
• These units are part of deferred director's compensation and include dividend equivalents.
• The units will be settled in cash or common stock upon Narayen's retirement from the Board of Directors.
• The acquisition price per unit was $24.29, totaling an acquisition value of $49,999.99.
• Following this transaction, Narayen beneficially owns 200,879.336 phantom stock units directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents a routine part of executive compensation and not a new strategic development or significant financial event.

Positives

• Director Narayen's acquisition of phantom stock units indicates continued commitment and alignment with the company's long-term performance.
• The phantom stock units are part of a deferred compensation plan, suggesting a structured approach to executive compensation and retention.

Future Outlook

The phantom stock units are to be settled in cash or common stock at the director's election following retirement from the Board of Directors, indicating a future event tied to the director's tenure.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions in the pharmaceutical industry, providing transparency on executive compensation and ownership stakes.

Stakeholder Impact

• Shareholders: Increased transparency regarding director compensation and ownership.
• Employees: Reinforces the company's compensation structure for its board members.
• Management: Demonstrates continued engagement and alignment of director interests with the company.

Next Steps

• Settlement of phantom stock units in cash or common stock upon Shantanu Narayen's retirement from the Board of Directors.

Key Dates

Keywords

Pfizer Inc., PFE, Form 4, Director, Shantanu Narayen, Phantom Stock Units, Deferred Compensation, Beneficial Ownership, SEC Filing